Investigation of pharmacokinetics, tissue distribution and excretion of schisandrin B in rats by HPLC–MS/MS

Skip to Navigation

EarlyView Article

  • Published: Sep 24, 2017
  • Author: Zhuo Wang, Linjun You, Yan Cheng, Kaiyong Hu, Zhanbo Wang, Yanan Cheng, Jin Yang, Yong Yang, Guangji Wang
  • Journal: Biomedical Chromatography


Schisandrin B has received much attention owing to its various biological activities. The present study was aimed at the formulation development of schisandrin B and investigation of the pharmacokinetic profiles, distribution and excretion of schisandrin B in Sprague–Dawley rats. In this study, micronized schisandrin B particles with particle size of 10–20 μm were chosen as the research object. Chromatographic separation was carried out on a BDS Hypersil C18 column (50 × 2.1 mm, i.d. 3.5 μm). Schisandrin B and deoxyschizandrin (internal standard) were detected without interference in the multiple reaction monitoring mode with positive electrospray ionization. The pharmacokinetic parameters were calculated by a noncompartmental method. The area under concentration–time curve and the maximum concentration showed a significant difference in gender. The calculated absolute oral bioavailability of schisandrin B was ~55.0% for female rat and 19.3% for male rat. Schisandrin B exhibited linear pharmacokinetics properties within the range of the tested oral dose (10, 20 and 40 mg/kg). After oral administration of schisandrin B, it was extensively distributed in ovary and adipose tissue. The result also showed very low urinary, biliary and fecal excretion of schisandrin B implying that schisandrin B was excreted mainly in the forms of metabolites.

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Most Viewed

Copyright Information

Interested in separation science? Visit our sister site

Copyright © 2017 John Wiley & Sons, Inc. All Rights Reserved